本文選題：非小細(xì)胞肺癌 + 腦轉(zhuǎn)移��； 參考：《廣東醫(yī)學(xué)》2017年07期

【摘要】：目的評(píng)價(jià)腦轉(zhuǎn)移灶體積與接受單純?nèi)X放療(whole brain radiotherapy,WBRT)的非小細(xì)胞肺癌(non-small cell lung cancer,NSCLC)腦轉(zhuǎn)移患者預(yù)后的關(guān)系。方法回顧性分析2010年8月至2014年12月就診于我院,并接受單純WBRT的54例NSCLC腦轉(zhuǎn)移患者,WBRT劑量為40 Gy/20 F。放療前行腦部MRI檢查,計(jì)算腦部轉(zhuǎn)移灶體積,并分為小腫瘤組和大腫瘤組;放療結(jié)束后3個(gè)月,復(fù)查腦部MRI評(píng)價(jià)近期療效;治療后每3個(gè)月復(fù)查MRI評(píng)價(jià)臨床療效直至疾病進(jìn)展或死亡,比較兩組患者的總生存期及1年生存率,同時(shí)對(duì)其預(yù)后影響因素進(jìn)行分析。結(jié)果小腫瘤組(體積7.65 cm~3)和大腫瘤組(體積7.65 cm~3)的總體緩解率和疾病控制率差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);全部患者的中位生存期為9.4個(gè)月,腦轉(zhuǎn)移灶體積7.65 cm~3患者的1年生存率較體積7.65 cm~3患者明顯降低(22.22%vs 51.85%,P=0.037)。多因素分析顯示:腫瘤體積、PS評(píng)分是影響總生存的獨(dú)立因素。結(jié)論腦內(nèi)轉(zhuǎn)移灶體積與接受單純WBRT的NSCLC腦轉(zhuǎn)移患者近期療效無(wú)明顯關(guān)系,但腦轉(zhuǎn)移灶體積7.65 cm~3患者的總生存期明顯縮短。
[Abstract]:Objective to evaluate the relationship between the volume of brain metastases and the prognosis of patients with non-small cell lung cancer (NSCLC) who received whole brain radiotherapy. Methods from August 2010 to December 2014, 54 patients with brain metastases from NSCLC received WBRT. The dose of WBRT was 40 Gy/20 F. Brain MRI was performed before radiotherapy and the volume of brain metastases was calculated and divided into small tumor group and large tumor group. After treatment, MRI was reexamined every 3 months to evaluate the clinical efficacy until the disease progression or death. The total survival time and 1 year survival rate were compared between the two groups, and the prognostic factors were analyzed. Results there was no significant difference in overall remission rate and disease control rate between small tumor group (volume 7.65 cm ~ (-3) and large tumor group (volume 7.65 cm ~ (-3), and the median survival time of all patients was 9.4 months. The 1-year survival rate in patients with brain metastases at 7.65 cm~3 was significantly lower than that in patients with volume 7.65 cm~3. Multivariate analysis showed that tumor volume and PS score were independent factors affecting total survival. Conclusion there is no significant relationship between the volume of brain metastases and the short-term curative effect of patients with NSCLC brain metastases receiving WBRT alone, but the total survival time of 7.65 cm~3 patients with brain metastases is significantly shortened.
【作者單位】： 中山大學(xué)孫逸仙紀(jì)念醫(yī)院放療科;
【分類(lèi)號(hào)】：R734.2;R730.55
，

本文編號(hào)：1952199